GlassScriptPhysician profile
Mounzer Alsamman
NPI 1700822160
$7,289.21
in general payments reported to CMS, 2019-2025
29 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $454 · 2021: $1,081 · 2022: $1,058 · 2023: $1,229 · 2024: $1,396 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,854.80 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $1,005.69 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $842.10 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $603.39 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $515.41 | 2019-2025 | |
| Lilly USA, LLC | $431.95 | 2024-2025 | Omvoh |
| Pfizer INC. | $239.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $191.54 | 2019-2023 | Dificid |
| Redhill Biopharma INC. | $191.21 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $173.23 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $155.37 | 2020-2023 | Suflave |
| Intercept Pharmaceuticals, INC. | $152.38 | 2020-2023 | Ocaliva |
| Organon LLC | $118.24 | 2024-2025 | Hadlima |
| Qol Medical, LLC | $102.01 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $101.08 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $96.65 | 2024-2025 | Vowst, Zenpep |
| Genzyme Corporation | $84.23 | 2022-2023 | |
| Allergan, INC. | $69.48 | 2019-2020 | |
| Celltrion USA INC. | $66.09 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $49.69 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $43.49 | 2021 | |
| Sandoz INC. | $33.70 | 2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $33.42 | 2023 | Rebyota |
| Ucb, INC. | $26.88 | 2023 | |
| Olympus America INC. | $25.48 | 2022 | |
| Dova Pharmaceuticals | $23.63 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $23.59 | 2025 | Iqirvo |
| Ethicon US, LLC | $23.18 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mounzer Alsamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.